方法：患者23例24眼玻璃体腔注射TA 4mg治疗黄斑视网膜前膜继发黄斑水肿，观察治疗前、后的最佳矫正视力、眼压、裂隙灯显微镜检查、荧光素眼底血管造影(fundus fluorescence angiography，FFA)和光学相干断层扫描(optical coherence tomography，OCT)的变化，采用SPSS 12.0软件进行统计学分析。

结果：TA治疗后10，30，90d与治疗前比较，视力明显提高(P<0.05)。OCT示黄斑中心视网膜厚度(central macular thickness，CMT)明显变薄(P<0.01)，术前平均厚度522±126μm，治疗后10，30，90d分别降低到264±115，245±128，286±131μm，黄斑水肿减轻，眼压升高7眼(29%)，白内障发生1例，未见其他与玻璃体注药相关的并发症。

结论：玻璃体腔注射TA治疗黄斑视网膜前膜继发黄斑水肿简单、安全、易操作，短期内可以迅速减轻黄斑水肿，并提高视力，部分患者在注射后6mo可能复发。

METHODS: Totally 23 patients(24 eyes)with macular edema caused by pre-retinal membrane of the macular were treated withintravitreal injection of 4mg TA. Best-corrected visual acuity(BCVA), intraocular pressure(IOP),slit-lamp examination, fundus fluorescein angiography(FFA)and optical coherence tomography(OCT)were performed before and after treatment. The SPSS 12.0 software was used for statistical analysis.

RESULTS: After 10, 30, 90d of treatment of TA, as compared with before treatment, visual acuity improved significantly(P<0.05), and central macular thickness(CMT)was significantly thinner(P<0.01). The average central macular thickness decreased from 522±126μm before treatment to 264±115μm, 245±128μm, 286±131μm at 10, 30, 90d after treatment. Macular edema reduced. IOP increased in 7 eyes(29%), one cataract case, no other complications associated with vitreous injection.

CONCLUSION:Intravitreal injection of TA in the treatment of macular edema caused by pre-retinal membrane of the macular is simple, safe and easy to operate. It can quickly reduce macular edema, and improve the visual acuity in the short term. Part of patients may recur after injection in the first half of the year.